ALFA Finder| Revenue growth | FY26 Enterprise Revenue ₹196.91 Cr vs FY25 ₹168.75 Cr (calculated). |
|---|---|
| Margins | Clinics ARPU ₹10-13k; Disease Reversal ₹50-60k per patient. |
| Demand visibility | Strong, footfall increased to 8.58 Lakh in FY26. |
| Management confidence | High, targeting 5 crore patients and 1,000 clinics by 2030. |
Growth
FY26 enterprise revenue reached ₹196.91 Cr; clinic revenue at ₹166.55 Cr (Services 61.95%, Products 38.05%).
Outlook
Targeting 1,000 clinics and 10 hospitals by 2028/2030. Scaling to 250-300 beds in 12-15 months.
Risks
High dependence on Maharashtra (247/320 clinics). Significant reliance on franchise network (~77% revenue share).
Earnings Call filed with NSE, NSE: MADHAVBAUG. Summary written with AI assistance from the document.
Vaidya Sane Ayurved Laboratories Ltd: key numbers
- Share price
- ₹140.25
- Market cap
- ₹147.4 Cr
- Revenue (annual)
- ₹106.9 Cr
- Net profit (annual)
- ₹8.99 Cr
- P/E (TTM)
- 16.4×Sector 35.3×
- Promoter holding
- 66.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaidya Sane Ayurved Laboratories Ltd
All →Vaidya Sane Ayurved Laboratories H1 FY27 Results: Net Loss of ₹0.2 Cr
Vaidya Sane Ayurved Laboratories Ltd reported revenue from operations of ₹58.7 Cr (+17.6% YoY) and a net loss of ₹0.2 Cr for H1 FY27.
- Key figure
- Net loss ₹0.2 Cr
Vaidya Sane Ayurved Laboratories Other Announcement
The Company has filed an undertaking confirming that Corporate Governance provisions under Regulation 27 of SEBI (LODR) are not applicable for the current quarter.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories held its 27th AGM on September 30, 2026. Shareholders considered the adoption of financial results, auditor re-appointments, and approval of ESOP 2026.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
Vaidya Sane Ayurved Laboratories Board Meeting Outcome
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories Other Announcement
Vaidya Sane Ayurved Laboratories filed a statement of deviation or variation in fund utilization pursuant to Regulation 32(1) for the quarter ended June 30, 2026.